Privium Fund Management B.V. Has $5.45 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Privium Fund Management B.V. raised its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 17.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 294,800 shares of the biotechnology company’s stock after acquiring an additional 43,820 shares during the quarter. Rocket Pharmaceuticals makes up 1.4% of Privium Fund Management B.V.’s portfolio, making the stock its 21st largest holding. Privium Fund Management B.V.’s holdings in Rocket Pharmaceuticals were worth $5,445,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its holdings in Rocket Pharmaceuticals by 31.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 764 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Rocket Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 582 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Rocket Pharmaceuticals in the third quarter valued at approximately $108,000. SG Americas Securities LLC acquired a new position in shares of Rocket Pharmaceuticals in the 3rd quarter worth approximately $113,000. Finally, Dana Investment Advisors Inc. grew its position in Rocket Pharmaceuticals by 4.4% during the 2nd quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 586 shares during the last quarter. Institutional investors and hedge funds own 98.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on RCKT shares. Canaccord Genuity Group reissued a “buy” rating and issued a $38.00 price objective on shares of Rocket Pharmaceuticals in a research note on Monday, September 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $52.00 price objective on shares of Rocket Pharmaceuticals in a research report on Friday. Scotiabank initiated coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 target price for the company. Finally, Chardan Capital reissued a “buy” rating and set a $62.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday, August 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $51.75.

Rocket Pharmaceuticals Stock Performance

RCKT stock opened at $17.45 on Friday. Rocket Pharmaceuticals, Inc. has a twelve month low of $15.98 and a twelve month high of $32.53. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.05. The company has a market cap of $1.59 billion, a P/E ratio of -6.35 and a beta of 1.09. The business’s fifty day moving average is $18.04 and its 200-day moving average is $20.42.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.